Rosetta Genomics Reports First Quarter 2008 Financi...(d development net $ 6400 $ 4781 ...)
Navigation Links
| HOME >> BIOLOGY >> TECHNOLOGY |
Rosetta Genomics Reports First Quarter 2008 Financial Results
Date:5/21/2008
d development, net $ 6,400 $ 4,781 $ 2,389 $ 1,161
Marketing and business
development 1,742 1,504 511 375
General and administrative 2,903 1,860 829 680
Operating loss 11,045 8,145 3,729 2,216
Financial expenses (income),
net 3,616 (538) 149 (200)
Net loss $ 14,661 $ 7,607 $ 3,878 $ 2,016
Basic and diluted net loss
per Ordinary share $ 1.32 $ 2.98 $ 0.33 $ 0.23
Weighted average number of
Ordinary shares used to
compute basic and diluted
net loss per Ordinary share 11,142,149 2,551,860 11,920,401 8,874,841
Contact: Media
Rachel Spielman
T: +1-212-583-2714
Investors
Ron Kamienchick
T: +1-646-509-1893
E: investors@rosettagenomics.com
'/>"/>
| SOURCE Rosetta Genomics Ltd Copyright©2008 PR Newswire. All rights reserved |
Related biology technology :
1. Rosetta Genomics Announces Annual General Meeting of Shareholders to be Held on September 24, 2007
2. NYU Medical Center Collaborates With Rosetta Genomics to Develop a microRNA-Based Diagnostic Test for Melanoma
3. Rosetta Genomics to Present at the American Association of Cancer Research (AACR) "Molecular Diagnostics in Cancer Therapeutic Development" Conference
4. Rosetta Genomics to Webcast Presentation at Maxim Group Growth Conference
5. Rosetta Genomics to Host and Webcast its R&D Day on Friday, October 26, 2007
6. Rosetta Genomics Will Host and Webcast its R&D Day on Friday, October 26, 2007
7. Rosetta Genomics Announces Initiation of In Vivo Studies Following Successful Completion of First Milestone in MicroRNA-based Therapeutic Program for Liver Cancer
8. Rosetta Genomics Selects PCR as Platform for its microRNA-based Diagnostics to be Launched in 2008, Licensed Nanogens MGB Probe Technology
9. Rosetta Genomics and Columbia University Medical Center to Develop MicroRNA-based Diagnostics for Leukemia and Non Hodgkin Lymphoma
10. Rosetta Genomics Announces Initiation of Expansion of US Operations to Facilitate Expected Product Launches in 2008
11. Henry Ford Hospital and Rosetta Genomics to Develop MicroRNA-based Diagnostics for Brain Cancer
Post Your Comments:
Breaking Biology Technology:Science Education Experts Discuss Solutions for Global Competitiveness at Scientific American Forum 2Science Education Experts Discuss Solutions for Global Competitiveness at Scientific American Forum 3Sirius Genomics Announces Change in Leadership 2MEDINA Scientists Select Genedata Screener for Lead Discovery from Natural Products 2MEDINA Scientists Select Genedata Screener for Lead Discovery from Natural Products 3MEDINA Scientists Select Genedata Screener for Lead Discovery from Natural Products 4Critical Step Toward Commercialization of Pre-Symptomatic Diagnosis of Ovarian Cancer Achieved by Arrayit Diagnostics 2Critical Step Toward Commercialization of Pre-Symptomatic Diagnosis of Ovarian Cancer Achieved by Arrayit Diagnostics 3Critical Step Toward Commercialization of Pre-Symptomatic Diagnosis of Ovarian Cancer Achieved by Arrayit Diagnostics 4
[0] Science Education Experts Discuss Solutions for Global Competitiveness at Scientific American Forum[0] Sirius Genomics Announces Change in Leadership[0] MEDINA Scientists Select Genedata Screener for Lead Discovery from Natural Products[0] Critical Step Toward Commercialization of Pre-Symptomatic Diagnosis of Ovarian Cancer Achieved by Arrayit Diagnostics
Other Biology Technology:Brown chemists create more efficient palladium fuel cell catalysts 2NeurogesX' Qutenza(TM) (NGX-4010) Receives Positive Committee Recommendation in European Union 2NeurogesX' Qutenza(TM) (NGX-4010) Receives Positive Committee Recommendation in European Union 3NeurogesX' Qutenza(TM) (NGX-4010) Receives Positive Committee Recommendation in European Union 4NeurogesX' Qutenza(TM) (NGX-4010) Receives Positive Committee Recommendation in European Union 5NeurogesX' Qutenza(TM) (NGX-4010) Receives Positive Committee Recommendation in European Union 6Enerkem announces plans to enter the United States with next-generation biofuels project in Mississippi 2Enerkem announces plans to enter the United States with next-generation biofuels project in Mississippi 3
Breaking Biology News(10 mins):Experts: Disease-resistant plants enhance profits, client satisfaction 2New science estimates carbon storage potential of US lands 2UCLA researchers engineer bacteria to turn carbon dioxide into liquid fuel 2John Hancock Launches Current Assumption Universal Life Policy 47800 1John Hancock Launches Current Assumption Universal Life Policy 47800 2John Hancock Launches Current Assumption Universal Life Policy 47800 3John Hancock Launches Current Assumption Universal Life Policy 47800 4Three New Programs Confer Degrees at MSPP Graduation on June 7 2009 47798 1Three New Programs Confer Degrees at MSPP Graduation on June 7 2009 47798 2Three New Programs Confer Degrees at MSPP Graduation on June 7 2009 47798 3Three New Programs Confer Degrees at MSPP Graduation on June 7 2009 47798 4Haemacure and Angiotech Enter License Distribution and Supply Agreements for Haemacures All Human Fibrin Sealant and Thrombin Products 47796 1Haemacure and Angiotech Enter License Distribution and Supply Agreements for Haemacures All Human Fibrin Sealant and Thrombin Products 47796 2Haemacure and Angiotech Enter License Distribution and Supply Agreements for Haemacures All Human Fibrin Sealant and Thrombin Products 47796 3Haemacure and Angiotech Enter License Distribution and Supply Agreements for Haemacures All Human Fibrin Sealant and Thrombin Products 47796 4
| Copyright © 2003-2009 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |